that there is a potential application of SAAD in treating superantigen-induced respiratory dysfunction and sepsis.
, one of the most direct and promising methods to prevent the development of sepsis might be the removal of systemically circulating SAgs from the body fl uid by extracorporeal blood purifi cation [10, 11] .
In an attempt to reduce the level of circulating SAgs, we have recently studied chemical modifi cation of polystyrene-based composite fi bers and developed a superantigen-adsorbing device (SAAD) [10] with a high affi nity for fi ve SAgs: staphylococcal enterotoxins A, B, and C; toxic shock syndrome toxin-1 (TSST-1); and streptococcal pyrogenic exotoxin A. Moreover, direct hemoperfusion with SAAD resulted in a signifi cant improvement of mortality in streptococcal-shock-affl icted rats [12] and retarded the shock onset time in S. aureus -infected, cecalligation-punctured rabbits [13] . However, two considerations accompany these models. First, the insuffi cient blood volume of these small animals does not allow monitoring of several physiological parameters at once. Second, toxin concentration in the circulating blood could not be controlled enough to maintain it at previously reported clinical levels. To overcome these problems, we have developed a toxin-concentration-controlled multiple organ dysfunction syndrome (MODS) model in swine that allows frequent blood sampling and monitoring with a Swan-Ganz thermodilution catheter [14] . In this model, major complications in gram-positive bacterial infection have been observed, such as respiratory and cardiovascular dysfunction.
The aim of this study was to examine the effi cacy of SAAD by sequential monitoring of physiological and serological parameters by blood sampling and the SwanGanz catheter. We used the swine sepsis model to allow us to control and maintain toxin concentrations at the clinical level.
Materials and Methods

Superantigen-Adsorbing Device (SAAD)
A polystyrene-based composite fi ber reinforced with polypropylene was prepared and chemically modifi ed by the method described elsewhere [10] . Briefl y, the composite fi ber was fi rst treated with N-methylol-␣ -chloroacetoamide in a mixture of sulfuric acid and nitrobenzene at 15 ° C for 2 h in the presence of paraformaldehyde. In the second step, the fi ber was reacted with tetraethylenepentamine in dimethylsulfoxide for 3 h at 30 ° C. Finally, the fi ber was reacted with 4-chlorophenylisocyanate in dimethylsulfoxide at 30 ° C for 1 h. After thorough washing with dimethylsulfoxide and then pyrogen-free water, sterilization was performed in pyrogenfree saline by gamma ray irradiation (25,000 Gy). The fi ber was maintained at 25 ° C until use.
Animals
Twelve conventional Landrace male pigs weighing 25-38 kg (age 2-3 months) were obtained from a local supplier. The anti-TSST-1 IgG antibody and anti-TSST-1 IgM antibody were under the detection level, as judged by enzyme-linked immunosorbent assay (ELISA). The LPS in the blood stream was also under the detection level ( ! 5 pg/ml).
Toxins TSST-1 was chromatographically purifi ed from the culture supernatants of the S. aureus FRI1169 strain, as described by Igarashi et al. [15] . The purifi ed preparation gave a single band on sodium dodecyl sulfate gel electrophoresis with Coomassie brilliant blue staining. The purifi ed TSST-1 had undetectable levels of LPS (limits of detection ! 5 pg/mg TSST-1), as judged by limulus assay.
TSST-1 was diluted to give a concentration of 10 g/ml, with physiological saline supplemented with 5% swine autoserum. The solution was fi ltered through a 0.22-m fi lter before use in the infusion treatment of animals.
Animal Experiments
For the animal experiment, the study protocol was reviewed and approved by the institutional animal research committee of both the Tokyo Medical University and Toray Industries, Inc.
The toxin-concentration-controlled sepsis model was developed in swine as previously reported [14] . Briefl y, swine were anesthetized by intramuscular administration of ketamine (17 mg/kg) and atropine sulfate (0.03 mg/kg) and maintained under anesthesia by mechanical ventilation with an oxygen-enriched air mixture containing 1% isofl urane [inspired oxygen fractional concentration (F i O 2 ) = 0.80] at a tidal volume of 10 ml/kg and a respiration rate of 15 strokes/min using a Servo Model 900D ventilator (SiemensElema, Stockholm, Sweden). The animals were also maintained under conditions of a constant body fl uid balance by continuous infusion of physiological saline at 3 ml/kg/h from the epiotic vein. The right carotid artery was cannulated for monitoring arterial blood pressure and heart rate (HR) and for sampling of the arterial blood samples subjected to blood gas analysis, hematology, and blood chemistry. The right jugular vein was cannulated with a Swan-Ganz Opticath thermodilution catheter (Abbott Inc., Abbott Park, Ill., USA). The cardiac output (CO) and oxygen saturation of mixed venous blood (S v O 2 ) were measured with an Oxymetrix 3 (Abbott Inc., Redwood City, Calif., USA), and monitoring of pulmonary arterial pressure, central venous pressure, and pulmonary capillary wedge pressure was carried out with a Model 54S analyzer (Hewlett Packard, Palo Alto, Calif., USA). The mixed venous blood samples were subjected to blood gas analysis. The infusion port of the thermodilution catheter was connected to an infusion line unit that had two injection ports: one for continuous infusion of physiological saline at 3 ml/kg/h to maintain the body fl uid balance in the animal, and the other for continuous infusion of TSST-1 and LPS. After the connection was completed, the animal was maintained under continuous infusion of physiological saline via the thermodilution catheter rather than via the epiotic vein, and mechanical ventilation was carried out with an air mixture (F i O 2 = 0.21) containing 1% isofl urane for recovery from the effects of the surgery. Twelve swine that had been treated were randomly allocated to the following two groups (n = 6 each): the SAAD group treated with hemoperfusion through a SAAD column, and the control group treated with hemoperfusion through an empty column having the same priming volume as that of the SAAD column. A statistical difference in mean body weight was not observed ( table  1 ) . The entire priming volume of the column, including circuit, was 200 ml. This priming volume did not compromise vital functions of normal swine (data not shown).
After the baseline values of the cardiac and respiratory function parameters were recorded, a TSST-1 solution (10 g/ml) was infused at 0.2 ml/kg/h for 5 h through the infusion port of the thermodilution catheter. After a 1-hour interval, the LPS solution (10 g/ml) was infused into the animals at 1 ml/kg/h for 1 h through the same infusion port that had been used for TSST-1 infusion. Direct hemoperfusion was performed at a fl ow rate of 80 ml/min using the left jugular vein into which a double-lumen catheter (11 Fr, 15 cm length, Medikit Co., Tokyo, Japan) was inserted. Hemoperfusion was initiated immediately after TSST-1 infusion started and continued for 8 h. The SAAD column was exchanged 4 h after the perfusion was initiated, and two columns were used in total. The double-lumen catheters were connected to the inlet and the outlet of the extracorporeal circuit for continuous hemodiafi ltration (MC-525, Toray Medical Co., Tokyo, Japan). The SAAD and control columns were washed with 2,000 ml of saline and pretreated with 2,500 U of heparin. From the anti-coagulant port, heparin was injected in one shot at a dose of 200 U/kg at the beginning of perfusion and then continuously infused at 200 U/ kg/h throughout the hemoperfusion period.
Measurement
Cardiac and respiratory monitoring indicated that all animals that received the surgical operation described above recovered from the effects of the surgery within 30 min of completion. Thus, the normal baseline levels of the parameters were recorded at 30 min after the completion of the surgery: HR = 100 8 15 beats/ min, mean arterial pressure (MAP) = 90 8 10 mm Hg, partial arterial oxygen pressure (PaO 2 ) = 90 8 10 Torr (12 8 1.3 kPa), and S v O 2 = 70 8 10%. The cardiac and respiratory function parameters were monitored continuously for 10 h from the initiation of the TSST-1 continuous infusion; however, three animals (one in the SAAD-perfused group and two in the control group) had died before the 10-hours observation. For this reason, differences between the SAAD-treated and control groups were statistically analyzed at two time points: fi rst, at 6 h after the TSST-1 infusion was initiated (T6), the time point at which TSST-1-induced MODS were observed [14] ; then at 8 h after TSST-1 infusion was initiated (T8), the time point at which LPS infusion and hemoperfusion were completed. Another reason we chose T8 is that it was the fi nal time point at which all animals were alive and the numbers of swine between the two groups were equal. After 10 h, for the animals who remained alive, the arterial catheter and thermodilution catheter were withdrawn and the wounds were closed surgically and maintained under anesthesia for 14 h (a total of 24 h) to observe the effect on mortality. After examination at 24 h, the animals were sacrifi ced with a lethal dose of sodium pentobarbital.
TSST-1 levels were determined by ELISA, as described previously [6] . The detection limit was 10 pg/ml. Clearance of TSST-1 was calculated as CL = [(Ci -Co)/Ci] ! QB, where Ci = TSST-1 concentration at the inlet of the column; Co = TSST-1 concentration at the outlet of the column; and QB = fl ow rate of the blood. Serum anti-TSST-1 IgG or IgM antibodies were determined by ELISA. Briefl y, samples were diluted 1,000-fold to avoid nonspecifi c reactions and then applied to a TSST-1 immobilized ELISA plate. Then anti TSST-1 antibodies were detected by anti-swine IgG (KPL Inc., Gaitherburg, Md., USA) or IgM (Serotec Ltd., Oxford, UK) antibodies. LPS was measured with a commercially available limulus assay kit (Wako Pure Chemicals, Osaka, Japan).
Interferon gamma (IFN-␥ ) and tumor necrosis factor alpha (TNF ␣ ) were quantifi ed with a colorimetric ELISA kit (Endogen Inc., Wo- burn, Mass., USA). Blood gas analysis was performed on an ABL-520 blood gas analyzer (Radiometer, Copenhagen, Denmark), and the measured values were standardized to body temperature. Hematological parameters and blood chemistry parameters were determined by standard methods at Tokyo Medical University, Hachioji Medical Center.
Statistical Analysis
All data in each group are presented as the mean 8 SD of all 6 animals. Data were evaluated using StatView 5.0 (the SAS Institute Inc., Cary, N.C., USA) software. For each parameter, the statistical signifi cance of the difference between the baseline value and the value at T6 or T8, or the difference between the concentration of TSST-1 at the inlet and the outlet of SAAD column was tested by paired t test at a signifi cance level of p ! 0.05. Correlations between the parameters were tested by regression analysis at a signifi cance level of p ! 0.05.
Differences between the SAAD-treated and control groups were statistically analyzed at T6 and T8 using the Student's t test at a signifi cance level of p ! 0.05. To test for the difference between the SAAD-perfused and control groups, an analysis of covariance (ANCOVA) was performed. In this model, ⌬ PVR was treated as an outcome variable; ⌬ WBC was treated as a covariate; and treatment (SAAD or control) was the relevant factor.
Results
Effect of SAAD on Survival
The result of SAAD treatment in this toxin-concentration-controlled swine sepsis model is depicted in fi gure 1 . All animals administered TSST-1 or LPS alone at the same dose survived for 24 h (data not shown). The SAADperfused group had signifi cantly less mortality at 24 h after initiation of the TSST-1 infusion [67% (SAAD) vs. 0% (control), p ! 0.05].
Effect of SAAD on Respiratory Dysfunction
The baseline values of respiratory function, PaO 2 , SaO 2 , alveolar-arterial oxygen tension difference (AaDO 2 ), and arteriovenous shunt ratio (Qs/Qt), were not signifi cantly different between the SAAD-perfused and control groups ( table 1 ). In the control group, administration of TSST-1 (10 g/kg) produced progressive and statistically signifi cant changes from the baseline values in PaO 2 and Qs/Qt that reached 77 8 15 Torr and 15.3 8 14.5%, respectively (p ! 0.05 compared with the baseline value), at T6. Additional administration of LPS that was initiated after a 1-hour interval from the completion of TSST-1 infusion produced a further decrease of PaO 2 and further increase of Qs/Qt; at T8, these parameters reached 58 8 13 Torr and 38.7 8 18.7%, respectively, and the P/F ratio reached 275, which meets the criteria of acute lung injury [16] . Furthermore, changes in SaO 2 and AaDO 2 from the baseline values were statistically significant at T8. In the SAAD-perfused group, changes in PaO 2 , SaO 2 , A-aDO 2 , and Qs/Qt from the baseline values were not observed at T6. Differences in PaO 2 between the baseline value and T8 were statistically signifi cant (p ! 0.05); however, the differences in SaO 2 , A-aDO 2 , and Qs/ Qt were not statistically signifi cant (p = 0.08, 0.14, and 0.053, respectively). 
Effect of SAAD on Cardiovascular Function
Baseline values of cardiovascular functions, such as CO, HR, mean arterial pressure (MAP), pulmonary vascular resistance (PVR), and oxygen delivery (DO 2 ), were not signifi cantly different between the two groups ( table   1 ) . In control animals, administration of TSST-1 (10 g/ kg) produced a statistically signifi cant increase in CO, HR, PVR, and DO 2 that reached 5.4 8 0.9 liters/min, 164 8 21 beats/min, 297 8 146 dyn ؒ s/cm 5 , and 780 8 142 ml/min (p ! 0.05), respectively; however, the increase in MAP was not statistically signifi cant at T6. After the additional LPS administration, CO, HR, and MAP de- Changes from the baseline values in DO 2 , HR, and PVR exhibited no signifi cant differences between the SAADperfused and control groups.
Effect of SAAD on Hematological and Serological Parameters
At each observation time point during the fi rst 6 h, the decrease from the baseline value in white blood cell counts kg/h; endotoxin was administered from 6 to 7 h, and extracorporeal circulation was from 0 to 8 h. Statistical comparison was made at 6 h (after TSST-1 infusion terminated) and 8 h (after LPS infusion and hemoperfusion terminated). * p ! 0.05, Student's t test. ⌬ PVR was signifi cantly higher in the control group (p ! 0.01, ANCOVA). However, the difference was not observed after LPS was infused (data not shown).
Toxin Concentrations, Toxin Clearance, and Cytokine Concentration
The systemically circulating toxin concentration was measured. As shown in fi gure 4 a, the TSST-1 concentration was maintained at previously reported clinical levels [6, 7] . However, while the TSST-1 concentration in the circulating blood was not statistically different between the SAAD-perfused and control groups ( fi g. 4 a), statistical differences were observed between the TSST-1 concentration at the inlet and the outlet of the SAAD column ( fi g. 4 b). Clearances of TSST-1 in both groups at 1, 2, 3, 5, 6 and 7 h after TSST-1 infusion was initiated ( fi g. 4 c) were also statistically different. The concentration of LPS tended to be higher in the control group, but the difference was not statistically signifi cant [2.2 8 1.7 ng/ml (SAAD) vs. 7.7 8 8.8 ng/ml (control), p = 0.33] at T8 ( fi g. TNF ␣ was detected in the circulating blood after LPS infusion, and a statistical difference between the two groups was not observed at T8 [4,328 8 2,475 (SAAD) vs. 4,104 8 2,004 pg/ml (control), p = 0.87]. Unfortunately, because we could not purchase reliable assays, other cytokines, such as the swine interleukins 6 and 8, could not be investigated.
Discussion
As previously reported, superantigen adsorption by SAAD improves the survival rate and retards the shock onset time in animal gram-positive bacterial sepsis models [12, 13] . However, these animals are too small for the monitoring of several physiological parameters, and tox- in concentrations in the circulating blood cannot be controlled and maintained at clinical levels. To overcome these problems, we have developed a sepsis model in swine that is toxin concentration controlled and with which a Swan-Ganz catheter can be used sepsis model in swine [14] ; in addition, this model is not lethal. Laboratory animals are intrinsically resistant to the toxicity of SAg and require far higher doses of SAg than do humans to induce shock; for this reason, prior sensitization with D -galactosamine or co-administration with LPS are used to induce lethality in low-dose, SAg-administration animal models [4, 8] . In this model, D -galactosamine was not used because of its hepatotoxicity; to enhance relative TSST-1 toxicity, LPS was infused instead of increasing the TSST-1 concentration to nonclinical levels [6, 7] .
Direct hemoperfusion by SAAD was performed for 8 h during the course of the toxin infusion, and two subjects were evaluated. The evaluations included observation of the effect of SAAD treatment on the prevention of toxin-induced death and examination of physiological changes that affect the survival rate.
Hemoadsorption for 8 h over a SAAD column is clearly associated with a highly signifi cant reduction in mortality ( fi g. 1 ). An improvement in respiratory functions was the major fi nding that contributes to the survival benefi t in terms of the effect on pathological phenomena at T6 (i.e. before LPS infusion was started). As shown in table 1 , MODS were induced, and signifi cant deterioration in PaO 2 , Qs/Qt, CO, and DO 2 was observed in control animals. In terms of these changes, Qs/Qt and PaO 2 were signifi cantly improved by SAAD treatment ( fi g. 2 ). We previously reported that TSST-1-induced infi ltration of WBC into the lung is one of the causes of respiratory failure, which is measured as the correlation between the decrease in WBC counts and increase in PVR [14] . In this study, a statistically signifi cant correlation was observed between the decrease in the WBC count and increase in the PVR, which indicates the infi ltration of WBC into the lung in individual animals for the entire 6-hour observation period in both the SAAD-treated and control groups.
As shown in fi gure 3 , the increase of ⌬ PVR was significantly higher in the control group. These results suggest that SAAD prevented the amelioration of pulmonary damage during the TSST-1 infusion period. Additionally, the prevention of hypoxia resulted in the prevention of a hyper-output state ( fi g. 2 d).
We measured toxin concentration in the circulating blood to evaluate the effi cacy of SAAD in eliminating SAg. Decreases in TSST-1 concentration between the blood samples from the inlet and the outlet of the SAAD column were statistically signifi cant at 1, 2, and 3 h after the perfusion was initiated or after exchanging the SAAD column (T1, T2, T3, T5, T6, and T7) ( fi g. 4 b). However, the difference in the concentration of the systemically circulating toxin in the two groups was not statistically signifi cant ( fi g. 4 a). Calculated from the clearances of TSST-1 by the SAAD column, 16% of infused TSST-1 was adsorbed on the SAAD column. This result could be interpreted to mean that the removal of TSST-1 by the SAAD resulted in a reduction in cytokine production and suppressed the TSST-1 toxicity; however, it does not seems plausible that a 16% reduction in the circulating TSST-1 concentration would be suffi cient to account for the marked effect on mortality.
Fenwick et al. [12] have reported that superantigen removal contributes, in part, to the improvement of septic rats treated with SAAD. Other studies in animal models and in vitro studies indicate [10, 12, 13] that SAAD also adsorbs other toxins or infl ammatory cytokines, and this adsorption activity is speculated to be one of the other possible merits of SAAD. To examine this hypothesis, adsorption of LPS, TNF ␣ , and IFN-␥ were measured in the blood circulation. Adsorption of LPS by SAAD has been observed in an in vitro study [10] ; however, in the current study the activity was insuffi cient to reduce the level of LPS in the circulating blood ( fi g. 4 d).
Serum TNF ␣ remained undetectable ( fi g. 4 e), while serum IFN-␥ increased and was statistically lower in the SAAD group at T4, T5, and T6 (p ! 0.05; fi g. 4 f). Although the synergistic effect of SAg and LPS is controversial in human sepsis, it has been convincingly demonstrated that SAg and LPS effi ciently synergize in the induction of lethal shock in animal models [17, 18] . This synergism is T cell dependent and the key mediator appears to be IFN-␥ because neutralizing antibodies to it are inhibitory [19] . In the present model, decreased concentration of IFN-␥ was effective not only in reducing infl ammation but also may have reduced the synergistic effect between SAg and LPS, which resulted in the improvement of mortality after LPS-induced shock. However, amelioration of the cardiovascular deterioration that was induced with LPS infusion was not observed in the SAAD-treated group at T8. Additional cytokines or other infl ammatory mediators will have to be examined in further studies to ascertain whether cytokine removal is a contributing benefi t.
In conclusion, the present study shows that blood purifi cation by SAAD perfusion resulted in a signifi cant reduction in mortality in this septic swine model. One of the mechanisms for reduction in mortality is the super-antigen adsorption that resulted in the improvement of respiration by attenuation of the damage infl icted by activated WBC. Another mechanism is the reduction of IFN-␥ that we speculate reduced the synergistic effect between SAg and LPS. These results suggest that hemoperfusion and removal of superantigens as well as other infl ammatory factors merits further study as a possible treatment strategy for gram-positive bacterial sepsis and organ dysfunction. In parallel, further work in animal models is necessary to clarify the mechanisms of action by which the impact on mortality reported here actually occurs.
